The effect of exposure to thiazolidinediones on the development of head-and-neck cancer in patients with diabetes mellitus
Background: Thiazolidinediones (TZDs) are proliferator-activated receptor-γ (PPAR-γ) ligands with a variety of metabolic activities approved for the treatment of type 2 diabetes mellitus. In addition to being potent hypoglycemic agents, they are recognized through in-vitro studies as having antiprol...
Main Authors: | Rangaswamy Govindarajan, Eric R Siegel |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-11-01
|
Series: | Translational Research in Oral Oncology |
Online Access: | https://doi.org/10.1177/2057178X17739809 |
Similar Items
-
Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis
by: Yang Liu, et al.
Published: (2018-01-01) -
Thiazolidinedione and cardiovascular risk in type 2 diabetes mellitus
by: Yenny Yenny
Published: (2016-04-01) -
To evaluate the effects of thiazolidinediones on blood lipid levels in patients with type 2 diabetes mellitus.
by: Tai-Cheng Yu, et al.
Published: (2008) -
The evaluation of dyslipidemia benefit effect of Thiazolidinediones with Statins in patients with type 2 diabetes mellitus
by: Hou-Jen Huang, et al.
Published: (2008) -
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
by: Jaehyun Bae, et al.
Published: (2021-05-01)